T. Rowe Price Associates’s Summit Therapeutics SMMT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $83.1M | Sell |
3,905,148
-2,652,656
| -40% | -$56.4M | 0.01% | 611 |
|
|
2025
Q1 | $127M | Sell |
6,557,804
-123
| -0% | -$2.37K | 0.02% | 514 |
|
|
2024
Q4 | $117M | Buy |
6,557,927
+1,118,270
| +21% | +$20M | 0.01% | 541 |
|
|
2024
Q3 | $119M | Buy |
5,439,657
+3,397,557
| +166% | +$74.4M | 0.01% | 528 |
|
|
2024
Q2 | $15.9M | Buy |
2,042,100
+2,008,955
| +6,061% | +$15.7M | ﹤0.01% | 1013 |
|
|
2024
Q1 | $138K | Buy |
33,145
+5,139
| +18% | +$21.4K | ﹤0.01% | 2715 |
|
|
2023
Q4 | $74K | Buy |
28,006
+1,059
| +4% | +$2.8K | ﹤0.01% | 2758 |
|
|
2023
Q3 | $51K | Buy |
26,947
+3,435
| +15% | +$6.5K | ﹤0.01% | 2772 |
|
|
2023
Q2 | $60K | Buy |
+23,512
| New | +$60K | ﹤0.01% | 2776 |
|